Open access
TroFuse-032 study design: pembrolizumab plus sacituzumab tirumotecan or chemotherapy followed by pembrolizumab plus chemotherapy as neoadjuvant therapy for early-stage, triple-negative breast cancer or HR-low+/HER2- breast cancer.
P. Schmid
Javier Cortés
R. Hui
Norikazu Masuda
A. Garrido-Castro
D. Loirat
Zhi-Min Shao
Yeon-Hee Park
Jing Wei
F. Beca
U. Malhotra
Nadia Harbeck
Medicine
Abstract
CLINICAL TRIAL REGISTRATION NCT06966700 (ClinicalTrials.gov); EU CT 2024-520190-12 (EudraCT).